^
Association details:
Evidence:
Evidence Level:
Sensitive: C3 – Early Trials
Title:

Kintara Therapeutics Reports 10 Months Progression-Free Survival in Newly-Diagnosed MGMT-unmethylated GBM from Ongoing MD Anderson Cancer Center Phase 2 Study

Published date:
11/19/2020
Excerpt:
...two Phase 2 clinical trials evaluating VAL-083 in patients with MGMT-unmethylated GBM...In newly-diagnosed patients receiving VAL-083 as adjuvant therapy following treatment with radiation and TMZ, for the 27 efficacy evaluable patients (of a planned up to 36 patients) as of the data cut-off of October 23, 2020, median progression-free survival (PFS) is currently 10.0 months (confidence interval: CI 7.6-10.8).
Evidence Level:
Sensitive: C4 – Case Studies
Title:

PHASE 2 STUDY OF VAL-083 AND RADIOTHERAPY IN NEWLY DIAGNOSED MGMT-UNMETHYLATED GBM: CASE STUDY REPORTS

Published date:
09/08/2023
Excerpt:
The first, a 32-yo woman, WHO Gr. 4 GBM (MGMT unmethylated), who received conventional radiotherapy with concurrent chemotherapy with VAL-083 followed by adjuvant VAL-083, for a total of 13 cycles of VAL-083. This patient is tumor free suvival more than 4 years till last follow-up (Mar 2023 ).
DOI:
https://doi.org/10.1093/neuonc/noad137.275